Breaks Categories: News

TuesdayJun 27, 2017 9:27 am

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Announces Acquisition of W Marketing, Inc.

Education technology company ProBility Media Corp. (OTCQB: PBYA) this morning announced that it has closed on its acquisition of W Marketing, Inc., a profitable, revenue-generating provider of National Electrical Codes (NECs) to the electrical and construction industries. “The closing of the acquisition of W Marketing highlights our commitment to aggressively building an international brand for education, training and compliance dedicated to the skilled trades,” Noah Davis, president and chief operating officer of ProBility, stated in the news release. “With the aggressive push from the current administration and the anticipated apprenticeship program, ProBility is positioned to take advantage of the projected…

Continue Reading

TuesdayJun 27, 2017 9:02 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Subsidiary Receives Major Purchase Order from Premier Biomedical (BIEI)

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced that its recently-acquired DIGS Hydro subsidiary has received a major purchase order from Premier Biomedical (OTCQB: BIEI). DIGS Hydro has already received the initial payment for this order, with final payment due upon delivery. “This opportunity for both SinglePoint and DIGS Hydro is fantastic,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “We have been working very hard on making acquisitions and inside sales to boost revenues. To have this subsidiary execute on its business plan and generate major revenue for SinglePoint is exactly what we want to…

Continue Reading

MondayJun 26, 2017 3:44 pm

NetworkNewsBreaks – Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) Announces Commencement of Drilling at Sully Property

Mineral exploration and development company Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) today announced that its drilling contractor, FB Drilling Ltd., has mobilized to the E3 Target on its Sully Project and has commenced drilling. Ongoing exploration activities are focused on the discovery of sedimentary exhalative (SEDEX) deposits, which serve as the most important source of a number of ores, including zinc, lead and barite. As previously reported, the E3 target at the 1,375-hectacre Sully Project located in British Columbia, Canada, features a promising gravity anomaly. This anomaly will be tested for the first time as part of these drilling…

Continue Reading

MondayJun 26, 2017 12:32 pm

NetworkNewsBreaks – Semnur Pharmaceuticals, Inc.’s (NASDAQ: SRNE) SP-102 Phase 1/2 Trial Meets Primary Endpoint, Preparing for Safety and Efficacy Studies; Shares Surge

Shares of Semnur Pharmaceuticals (NASDAQ: SRNE) are up 12.1% after the company posted positive data from is phase 1/2 pharmacokinetic bridging trial of its lead product, SP-102, for the treatment of lumbar radicular pain. The trial achieved its primary pharmacokinetic endpoint and demonstrated that a single epidural injection of SP-102 can provide a sustained analgesic effect for one month. Semnur said it will now move forward with the next stage of clinical trials. "We are very excited with the data from this first-in-human proof-of-principle study, which allows us to proceed with the planned Phase 3 safety and efficacy trials in…

Continue Reading

MondayJun 26, 2017 11:32 am

NetworkNewsBreaks – Neothetics, Inc. (NASDAQ: NEOT) Shares Sink to New Low on Disappointing Phase 2 Study of LIPO-202

Shares of Neothetics (NASDAQ: NEOT) plummeted more than 69% to a new 52-week low of $0.70 after the specialty pharmaceutical company said its fat reduction candidate, LIPO-202-CL-31, failed to demonstrate improvement on any efficacy measurements or separation from placebo. LIPO-202 continued to show a benign safety profile. “We are determining the path forward for the company,” Kim Kamdar, Ph.D., a member of Neothetics’ operating committee and board of directors, stated in the news release. “Our primary objective is to maximize value for our shareholders, and we will be expeditious and diligent in deciding next steps. We will share our future…

Continue Reading

MondayJun 26, 2017 11:29 am

NetworkNewsBreaks – 22nd Century Group, Inc. (NYSE: XXII) Added to Russell Microcap® Index

22nd Century Group (NYSE MKT: XXII) this morning announced its inclusion to the Russell Microcap® Index. The one-year membership to the index means the plant biotech company is automatically included in the appropriate growth and value style indexes. “We are pleased to be added to the Russell Microcap Index. Our inclusion will generate further interest in the Company’s stock among those investors in the investment community who may be less familiar with 22nd Century Group,” 22nd Century Group president and CEO Henry Sicignano, III, stated in the news release. Shares of 22nd Century Group are down 2.1% at $1.84, trading…

Continue Reading

MondayJun 26, 2017 9:48 am

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends University of Guelph Research Agreement through 2018

ABcann Global Corporation (TSXV: ABCN) this morning announced that it has amended and extended the research contract currently in place between its Canadian operating subsidiary, ABcann Medicinals Inc., and the University of Guelph in Ontario, Canada. The agreement, which is focused on controlled environment production of medicinal cannabis, now extends to December 31, 2018, and offers an option to extend further if mutually agreed upon. “ABcann has pursued a unique approach to controlled environment production of cannabis designed to standardize the production and quality of medical compounds,” Dr. Michael Dixon, director of the Controlled Environment Systems Research Facility at the…

Continue Reading

FridayJun 23, 2017 1:15 pm

NetworkNewsBreaks – BioDelivery Sciences (NASDAQ: BDSI) Receives Health Canada Approval of BELBUCA®; Plans to Launch In Early 2018

BioDelivery Sciences (NASDAQ: BDSI) this morning said that Health Canada has issued a Notice of Compliance (NOC) approving BELBUCA® for the management of opioid responsive pain severe enough to require daily, continuous, long-term treatment for which alternative options are inadequate. Approval is an important milestone for the company as it intends to commercialize BELBUCA in Canada through a partner. The launch of BELBUCA in Canada is expected in early 2018. "We believe BELBUCA offers important and distinctive advantages for those dealing with chronic pain, and we look forward to engaging with a commercial partner in Canada and for availability of…

Continue Reading

FridayJun 23, 2017 1:13 pm

NetworkNewsBreaks – ParkerVision, Inc. (NASDAQ: PRKR) Shares Plunge on Holding Decision in Infringement Case Against Apple (NASDAQ: AAPL)

Shares of ParkerVision (NASDAQ: PRKR) plunged 14% mid-day on news that the Regional Court of Munich is holding its decision in the ParkerVision v. Apple (NASDAQ: AAPL) infringement case until after the German Federal Patent Court rules on the associated pending nullity action. Similarly, the company’s final resolution in its German case against LG is pending the same action. The company expects a preliminary nullity decision before the end of 2017. “We remain optimistic that the Federal Patent Court will come to that conclusion yet this year enabling us to request the Regional Court to issue an enforceable injunction against…

Continue Reading

FridayJun 23, 2017 11:44 am

NetworkNewsBreaks – AVEO Oncology (NASDAQ: AVEO) Shares Skyrocket on CHMP’s Recommendation to Approve Tivozanib

AVEO Oncology (NASDAQ: AVEO) shares soared over 80% this morning on news that FOTIVDA™ has been recommended for approval as a treatment for patients with advanced renal cell carcinoma (RCC) by the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency. The CHMP's recommendation is referred to the European Commission, which is anticipated to make its final decision in approximately 67 days. Approval of FOTIVDA™ would also result in R&D reimbursement and milestone payments for the company. “If the European Commission grants marketing approval for tivozanib, it would trigger a $4 million research…

Continue Reading